NeuroSense GM awarded 200,000 share grant

Binder Hagit reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Binder Hagit reported acquisition or exercise transactions in this Form 4 filing.

NeuroSense Therapeutics Ltd. granted General Manager Hagit Binder 200,000 Ordinary Shares as a share-based compensation award, recorded at a price of $0.0000 per share. Following this grant, Binder directly holds 521,806 Ordinary Shares.

The award consists of restricted shares that vest in equal quarterly installments over a two-year period starting on March 26, 2026, conditioned on Binder’s continued service with the company at each vesting date. To qualify for certain Israeli tax benefits under Section 102, the securities must be registered in the name of a trustee, but they are reported here as directly owned by Binder.

Insider Trade Summary

Grant/Award: 200,000 shares

Grant/Award 1 txn

Insider Binder Hagit

Role General Manager

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	200,000	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 521,806 shares (Direct)

Footnotes (2)

1. F1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee.
2. F2. The restricted shares vest in equal quarterly installments over a two-year period, commencing on the grant date of March 26, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NeuroSense Therapeutics (NRSN) report for Hagit Binder?

NeuroSense Therapeutics reported that General Manager Hagit Binder received a grant of 200,000 Ordinary Shares as compensation. The Form 4 shows this as an acquisition at $0.0000 per share, increasing her direct holdings to 521,806 Ordinary Shares after the transaction.

How many NeuroSense Therapeutics (NRSN) shares does Hagit Binder hold after the grant?

After the reported grant, Hagit Binder directly holds 521,806 Ordinary Shares of NeuroSense Therapeutics. This total reflects the addition of 200,000 restricted shares awarded on March 26, 2026, as part of her compensation, subject to the specified vesting conditions over two years.

Is the NeuroSense Therapeutics (NRSN) Form 4 transaction an open-market purchase or a grant?

The Form 4 transaction is a grant, not an open-market purchase. The filing classifies it under code “A” as a grant, award, or other acquisition, with 200,000 Ordinary Shares issued at a recorded price of $0.0000 per share as compensation to Hagit Binder.

What is the vesting schedule for Hagit Binder’s NeuroSense Therapeutics (NRSN) restricted shares?

The 200,000 restricted shares granted to Hagit Binder vest in equal quarterly installments over two years. Vesting starts on March 26, 2026, the grant date, and each installment requires her continued service with NeuroSense Therapeutics as of the relevant quarterly vesting date.

Why are Hagit Binder’s NeuroSense Therapeutics (NRSN) shares registered in a trustee’s name?

The filing explains that, to qualify for certain Israeli tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the 2018 Share Incentive Plan must be registered in a trustee’s name, even though they are reported as awarded to the employee or director.

Which compensation plan covers Hagit Binder’s share grant at NeuroSense Therapeutics (NRSN)?

The grant of 200,000 Ordinary Shares to Hagit Binder is made under NeuroSense Therapeutics’ 2018 Share Incentive Plan. The filing notes that, for tax purposes, securities under this plan are held by a trustee in accordance with Section 102 of the Israeli Tax Ordinance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/30/2026 - 08:49 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Binder Hagit

(Last) (First) (Middle)

C/O NEUROSENSE THERAPEUTICS LTD.

11 HAMENOFIM STREET, BUILDING B

(Street)

HERZLIYA 4672562

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
NeuroSense Therapeutics Ltd. [ NRSN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Manager

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/26/2026		A		200,000(2)	A	$0	521,806	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee.

2. The restricted shares vest in equal quarterly installments over a two-year period, commencing on the grant date of March 26, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

	/s/ Hagit Binder	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)